Integrated Platform of siRNA Drug Discovery
RNA interference using small interfering RNA (siRNA) molecules has emerged as a promising therapeutic modality. To accelerate the discovery of novel siRNAs, WuXi AppTec has established an integrated platform encompassing siRNA sequence design, chemical synthesis/modification, delivery ligand exploration, and activity/off-target assessment.
At the TIDES USA 2024 Conference, our scientists presented a poster showcasing the effectiveness of this platform in conducting a comprehensive study on complement component 5 (C5) siRNAs, identifying chemically modified C5-targeting siRNAs that exhibit potent inhibition of C5 mRNA with minimal off-target effects.
TIDES USA Poster_Integrated Platform of siRNA Drug Discovery
Related Content
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...
VIEW RESOURCEGouty arthritis is a common, painful inflammatory condition characterized by the deposition of monosodium urate (MSU) crystals in joints. This...
VIEW RESOURCE